Melanoma

Test Outperforms Traditional Tool in Predicting Melanoma Spread to Lymph Nodes

A prospective study shows the test more accurately identifies patients who may safely avoid biopsy compared to the Melanoma Institute Australia nomogram.

Melanoma

Why ctDNA Monitoring is Critical in Early Melanoma Recurrence Detection

NeoGenomics' study demonstrates how ctDNA monitoring enables earlier detection of MRD and recurrence risk in high-risk melanoma patients.

Melanoma

These Combined Biomarkers Help Identify Melanomas at Low Risk of Metastasis

The combined biomarkers, AMBRA1 and loricrin can be used to reliably stratify stage I and II melanomas at genuine low risk of progression.

Predictive Model IDs Melanoma Patients Best Suited for SLNB

Jun 16, 2023 | Melanoma

A new patient-centered approach more accurately identifies melanoma patients eligible for sentinel lymph node biopsy (SLNB).

Clinical Studies Evaluate DermaSensor’s Skin Cancer Detection Device

Mar 21, 2023 | Melanoma

DermaSensor presented a pooled analysis from clinical studies evaluating the performance of the company’s device in detecting skin cancer.

DermTech’s Melanoma Assay Gets VHA Recommendation

Feb 20, 2023 | Melanoma

The U.S. General Services Administration has recommended DermTech’s foundational melanoma assay for coverage by the VHA.

Biomarkers Predict Resistance to Immunotherapies in Melanoma

Nov 24, 2022 | Melanoma

Researchers found potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to cause progression of melanoma cells.

Roche Launches PRAME Antibody for Suspected Melanoma

Nov 21, 2022 | Melanoma

Roche has announced the launch of the PRAME Antibody to identify PRAME protein expression with suspected melanoma.

New AI Tech Predicts Diagnostic Concordance For Melanoma, Proscia Says

Nov 1, 2022 | Melanoma

Proscia released study results on new AI that predicts diagnostic agreement for melanoma, the deadliest form of skin cancer.

Proscia’s AI Selected for Skin Pathology

Sep 14, 2022 | Analytical Software Systems, Melanoma

Unilabs and Proscia have announced that the diagnostic group has chosen Proscia’s DermAI skin pathology solution.

InterVenn’s Melanoma Test Helps Oncologists Plan for Treatment

Jun 22, 2022 | Melanoma

InterVenn’s new melanoma test is commercially available as a glycoproteomics LDT that aids oncologists in planning treatment for melanoma.

New Biomarkers Can Predict Response to Melanoma Immunotherapy Treatment

Feb 18, 2022 | Melanoma

Researchers have discovered blood biomarkers that can help identify if someone suffering from Melanoma can benefit from immune checkpoint inhibitors.

Foundation Medicine Receives FDA Approval for its Tissue-Based Genomic Profiling Test

Dec 28, 2021 | Melanoma, Tissue Processing

FoundationOne CDx is used as a companion diagnostic for two groups of FDA-approved therapeutics in melanoma, which includes BRAF inhibitor monotherapies.

Virtual Histology Eliminates Need for Invasive Skin Biopsies

Nov 19, 2021 | Histology, Melanoma, Microscopy

Researchers used deep learning framework to transform microscopy images of intact skin into histochemically stained sections imaged on microscope slides.

AI Breakthrough Announced in Melanoma Detection

Oct 7, 2021 | Melanoma

Proscia has released study results on new technology that leverages AI to automatically detect melanoma with a high degree of accuracy.

Castle Biosciences to Acquire Myriad MyPath Laboratory

May 21, 2021 | Company News, Melanoma

Castle Biosciences’ acquisition of CLIA-certified Myriad MyPath Laboratory from Myriad Genetics will expand its suite of genomic tests for skin cancer.